iNtRON Biotechnology acquire U.S. FDA’s Orphan Drug Designation for Endolysin
iNtRON Biotechnology(CEO Kyung-Won Yoon), a new biologic developing company, announced on the 26th that its currently-developing bacillus anthracis based on endolysin called ‘N-Rephasin BAL200(hereinafter referring to BAL200)’ acquired Orphan Drug Designation(ODD) from the U.S. Food and Drug Admi...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.